Manuscripts should be accompanied by a cover letter signed by all co-authors which should include the following information statements:
- Information on prior or duplicate publication or submission elsewhere of any part of the work;
- A statement of financial or other relationships that might lead to conflict of interest;
- A statement that the manuscript has been read and approved by all the authors, that the requirements for authorship have been met, and that each author believes that the manuscript represents honest work; and
- The name, address, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs; and
- The authors should include the name, address and e-mail of four possible reviewers.
- Research Articles: Full-length articles should present new clinical or basic research data in a field related clinical pharmacology and translational research. The format should include title page, abstract (up to 250 words), introduction, methods, results, discussion and conclusion, references, figure legends, figures and/or tables
- Case Study: Detailed account of clinically important cases of common and rare conditions.
- Review: Summarizes the findings of others studies or experiments; attempts to identify trends or draw broader conclusions. Scholarly in nature but not a primary source or research article, however its references to other articles will include primary sources or research articles.
- Letters or Comments: It will include comments on papers published within 3 months. No more than 500-1000 words, one figure/table and 10 references.
- Communications: This format is suitable for preliminary scientific observations and case presentations that raise a novel clinical or scientific issue. Communications length will be no more than 1000 words, 2 figures or tables and 20 references.
- Scientific Perspectives: The aim of these articles is to discuss recent important scientific results and methodologies and to place them into a clinical and translational context. These articles can also propose a new hypothesis that contributes to the discussion in the field.
- Negative results: This format is suitable to publish negative results that are important to the field.
The following are general requirements for reporting within sections of all study designs and manuscript formats:
- Title Page : The title page will include (i) article title should be short, specific, and clear without abbreviations. The title will not exceed 150 characters. For clinical trials (particularly important for randomized trials and systematic reviews and meta-analyses) information about the study design be a part of the title; (ii) authors’ names, and affiliations; (iii) Corresponding author name, address, telephone and email address; (iv) Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: All information on support and financial issues from all authors relative to the research covered in the submitted manuscript must be disclosed regardless of date. Other financial information unrelated to the current research covering the past year will be documented at the end of the manuscript (see below); (v) Funding sources for study; (vi) A running head: Applis journals request a short running head or foot-line, usually no more than 40 characters (including letters and spaces) at the foot of the title page. Running heads are used within the editorial office for filing and locating manuscripts; (vii) Keywords: seven keywords; (viii) Disclaimers: An example of a disclaimer is an author’s statement that the views expressed in the submitted article are his or her own and not an official position of the institution or funder; (ix) Word counts: A word count for the text only (excluding abstract, acknowledgments, figure legends, and references). A separate word count for the Abstract is useful for the same reason; (x) Number of figures and tables; (xi)Conflict of Interest declaration: Editors may require conflict of interest declarations on the manuscript title page.
- Abstract :The abstract should provide the context or background for the study and should state the study’s purpose, basic procedures (selection of study participants, settings, measurements, analytical methods), main findings (giving specific effect sizes and their statistical and clinical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations, note important limitations, and not over interpret findings. Clinical trial abstracts should include items that the CONSORT group has identified as essential: (www.consort-statement.org/resources/downloads/extensions/consort-extension-for-abstracts-2008pdf/). The ICMJE recommends that journals publish the clinical trial registration number at the end of the abstract. The ICMJE also recommends that, when a registration number is available, authors list that number the first time they use a trial acronym to refer to the trial they are reporting or to other trials that they mention in the manuscript. If the data have been deposited in a public repository, authors should state at the end of the abstract the data set name, repository name and number.
- Introduction : Provide a context or background for the study (that is, the nature of the problem and its significance). State the specific purpose or research objective of, or hypothesis tested by, the study or observation.
- Methods : The guiding principle of the Methods section should be clarity about how and why a study was done in a particular way. The Methods section should aim to be sufficiently detailed such that others with access to the data would be able to reproduce the results. If an organization was paid or otherwise contracted to help conduct the research (examples include data collection and management), then this should be detailed in the methods. The Methods section should include a statement indicating that the research was approved or exempted from the need for review by the responsible review committee (institutional or national). If no formal ethics committee is available, a statement indicating that the research was conducted according to the principles of the Declaration of Helsinki should be included.
- Results : Present your results in logical sequence in the text, tables, and figures, giving the main or most important findings first. Do not repeat all the data in the tables or figures in the text; emphasize or summarize only the most important observations. Provide data on all primary and secondary outcomes identified in the Methods Section. Extra or supplementary materials and technical details can be placed in an appendix where they will be accessible but will not interrupt the flow of the text, or they can be published solely in the electronic version of the journal.
Give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and specify the statistical significance attached to them, if any. Restrict tables and figures to those needed to explain the argument of the paper and to assess supporting data. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Avoid nontechnical uses of technical terms in statistics, such as “random” (which implies a randomizing device), “normal,” “significant,” “correlations,” and “sample.”
- Discussion : Summarizes the main findings, and explore possible mechanisms or explanations for these findings. State the limitations of your study, and explore the implications of your findings for future research and for clinical practice or policy.
- Conclusions : Represents the Goals of the study but avoid unqualified statements and conclusions not adequately supported by the data. In particular, distinguish between clinical and statistical significance, and avoid making statements on economic benefits and costs unless the manuscript includes the appropriate economic data and analyses.
- References: Authors should provide direct references to original research sources whenever possible. References should not be used by authors, editors, or peer reviewers to promote self-interests. Do not use conference abstracts as references: they can be cited in the text, in parentheses, but not as page footnotes. References to papers accepted but not yet published should be designated as “in press” or “forthcoming.” Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source. Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, obtain written permission and confirmation of accuracy from the source of a personal communication. To minimize citation errors, references should be verified using either an electronic bibliographic source, such as PubMed, or print copies from original sources. Authors are responsible for checking that none of the references cite retracted articles except in the context of referring to the retraction.
- Figures & Table Guidelines: Figures should be either professionally drawn and photographed, or submitted as photographic quality digital prints. For X-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send high-resolution photographic image files. Letters, numbers, and symbols on figures should therefore be clear and consistent throughout, and large enough to remain legible when the figure is reduced for publication. Figures should be made as self-explanatory as possible, since many will be used directly in slide presentations. Titles and detailed explanations belong in the legends-not on the illustrations themselves. Photo micro-graphs should have internal scale markers. Symbols, arrows, or letters used in photo micro-graphs should contrast with the background. Figures should be numbered consecutively according to the order in which they have been cited in the text. If a figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce it. Permission is required irrespective of authorship.
- Illustrations (Figures) : Legends for illustrations (figures): Type or print out legends for illustrations using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend or publisher except for documents in the public domain.
- Legends for illustrations (figures) : Type or print out legends for illustrations using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend or publisher except for documents in the public domain.
- Units of Measurement:Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. Drug concentrations may be reported in either SI or mass units, but the alternative should be provided in parentheses where appropriate.
- Abbreviations and Symbols:Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement.
- Tables: Tables capture information concisely and display it efficiently; they also provide information at any desired level of detail and precision. Number tables consecutively in the order of their first citation in the text and supply a title for each. Titles in tables should be short but self-explanatory, containing information that allows readers to understand the table’s content without having to go back to the text. Give each column a short or an abbreviated heading. Authors should place explanatory matter in footnotes, not in the heading. Explain all nonstandard abbreviations in footnotes, and use symbols to explain information if needed. Symbols may vary from journal to journal (alphabet letter or such symbols as *, †, ‡, §), so check each journal’s instructions for authors for required practice. Identify statistical measures of variations, such as standard deviation and standard error of the mean. If you use data from another published or unpublished source, obtain permission and acknowledge that source-fully. Additional tables containing backup data too extensive to publish in print may be appropriate for publication in the electronic version of the journal, deposited with an archival service, or made available to readers directly by the authors. An appropriate statement should be added to the text to inform readers that this additional information is available and where it is located. Submit such tables for consideration with the paper so that they will be available to the peer reviewers.
- Supplemental Material: Supporting material that cannot be included, and which is not essential for inclusion, in the full text of the manuscript, but would nevertheless benefit the reader. It should not be essential to understand the conclusions of the paper but should contain data that are additional or complementary and directly relevant to the article content. We encourage authors to include supplementary information with their submissions whenever appropriate; for example, when the amount of material is too great to warrant inclusion in the main body of the paper, or when the material is in a format that cannot be represented in print (i.e. audio, video, three-dimensional representations, and other rich media as well as additional figures and tables). The supplemental material provides additional information that enhances the main text and is directly referenced within the text but is not critical to its assertions. Please note that atomic co-ordinates used to create molecular models described in a manuscript, unless deposited in a publicly available database, must be made available as Supplementary data. Although we do not limit the number or type of supplemental material items authors may include, we do require that they provide a relevant and useful expansion of the article, and that they are as well described as are figures and tables included within the body of the article. Good metadata of this material is key to discoverability and usefulness.
- Style and Format: Applis recommend authors to cite electronic references within parentheses in the text. Applis recommends authors to follow the standards summarized in the NLM’s International Committee of Medical Journal Editors (ICMJE). Reference Citation format: Only include references that have been cited in the body of the paper should be included.
- What is the scope of Applis Publishers?
- Are your publications peer reviewed?
- Do you restrict the length of articles?
- What article types do you publish?
- How can I submit my article?
- How quickly are articles published?
- Is there a print version?
- What are your Article publication charges (APCs)?
- Why are your charges set at these levels?
- Do you offer waivers or discounts?
- How do authors pay the author fee?
- Who is responsible for making or arranging the payment?
- Who holds copyright on Applis journal articles?
Article title: Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002 Jul 25;347(4):284-7.
More than six authors: List the first six authors followed by et al.Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6.
Organization as author: Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40(5):679-86.
Both personal authors and organization as author: Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169(6):2257-61.
No author given: 21st century heart solution may have a sting in the tail. BMJ. 2002;325(7357):184.
Article not in English: Ellingsen AE, Wilhelmsen I. Sykdomsangst blant medisin- og jusstudenter. Tidsskr Nor Laegeforen. 2002;122(8):785-7. Norwegian.
Volume with supplement: Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42 Suppl 2:S93-9.
Issue with supplement: Glauser TA. Integrating clinical trial data into clinical practice. Neurology. 2002;58(12 Suppl 7):S6-12.
Pagination in roman numerals: Chadwick R, Schuklenk U. The politics of ethical consensus finding. Bioethics. 2002;16(2):iii-v.
Article containing retraction: Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2002;63(2):169. Retraction of: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2000;61(12):909-11.
Article republished with corrections: Mansharamani M, Chilton BS. The reproductive importance of P-type ATPases. Mol Cell Endocrinol. 2002;188(1-2):22-5. Corrected and republished from: Mol Cell Endocrinol. 2001;183(1-2):123-6.
Books and Other Monographs: Personal author(s): Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
Chapter in a book: Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.
Conference proceedings: Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.
Conference paper: Christensen S, Oppacher F. An analysis of Koza’s computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.
Scientific or technical report: Yen GG (Oklahoma State University, School of Electrical and Computer Engineering, Stillwater, OK). Health monitoring on vibration signatures. Final report. Arlington (VA): Air Force Office of Scientific Research (US), Air Force Research Laboratory; 2002 Feb. Report No.: AFRLSRBLTR020123. Contract No.: F496209810049.
Patent: Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.
Journal article on the Internet: Sinha A, Madden J, Ross-Degnan D, Soumerai S, Platt R. Reduced risk of neonatal respiratory infections among breastfed girls but not boys. Pediatrics [serial online] 2003;112:e303.
Internet: http://pediatrics.aappublications.org/cgi/content/full/112/4/e303 (accessed 14 October 2003).
Monograph on the Internet: Foley KM, Gelband H, editors. Improving palliative care for cancer [Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from:http://www.nap.edu/books/0309074029/html/.
Blogs: Holt M. The Health Care Blog [Internet]. San Francisco: Matthew Holt. 2003 Oct – [cited 2009 Feb 13]. Available from: http://www.thehealthcareblog.com/the_health_care_blog/.
Homepage/Web site: Cancer-Pain.org [Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from: http://www.cancer-pain.org/.
Editorial Review & Publication: Authors must submit manuscripts to Applis Journals in electronic form. An initial cursory review by the EIC will validate that the paper content is appropriate both in scope and quality. If the paper is deemed inappropriate, it will be rejected without review. Otherwise, the EIC will decide to process the paper directly or assign it to one of the associate editors.
The assigned editor performs an initial review of the submission, and may decide to desk reject it or put it through the review process. The grounds for a submission being desk rejected at this stage include, but are not limited to, simultaneous double submission, submission of substantially the same version of a previously published paper, the subject of the paper being outside the coverage scope of respective journal, the paper obviously lacking in breadth, substance, quality or completeness.
If the Editor decides to put the submission through the regular review process, he/she may retain reviewers for expert opinions and detailed useful comments for the authors. The number of reviewers may range between 2 or 4, with the Editor optionally serving as a reviewer. In all but the most unusual cases, 3 external reviewers will be contacted.
The Editor makes an editorial decision on the submission, using reviewers’ comments and recommendations as input (only as input). If the reviews are not clear or detailed enough, or the reviews diverge substantially, the Editor may communicate with the reviewers and seek additional verbal comments, and use them as additional input. The Editor may send the authors some or all of the reviewers’ comments, and may withhold certain comments from the authors at his/her discretion.
The editorial decision may be one of
• Request for a minor revision,
• Request for a major revision,
• Conditional accept, and
• Unconditional accept.
In all cases of acceptance, the editor will seek input from the Editor-in-Chief.
If the author disagrees with the reject decision, he/she should communicate with the Editor and make his/her case and/or seek clarification. If the author wishes to appeal the decision, he/she should request the Editor to seek arbitration by the EIC. The EIC will review all materials and make a judgement on the merits of the appeal. The decision by the Editor-in-Chief is final.
Appeals: All authors have the right to appeal rejection of their manuscript. Authors can appeal directly by contacting the editorial office. Appeals will be reviewed in the context of the manuscript’s scientific content and its suitability for publication. The Editor-in-Chief’s decision on the appeal will be final.
Complaints: All complaints can be made directly to the editorial office. They will be happy to outline the complaint procedure in full.
Proofreading The Editorial Office of the journal will create the final version of the manuscript in the journal’s template and the PDF proof will be sent to the author for final proofreading before publication. Authors should carefully check the proofs for typographical or layout errors, and use the sticky notes tool to mark and explain any changes necessary.
Copyediting: After the manuscript is accepted for publication it will undergo a first stage of copy editing where the journal editors will correct any minor mistakes (such as punctuation or references) and check that all necessary information regarding the manuscript and authors has been provided.
Authors will receive an edited version of their manuscript for author copy editing after acceptance of the manuscript for publication. This is the last stage where any substantial copy editing changes to the text are allowed (the next stage—proofreading—is restricted to correcting typographical and layout errors).
Publication: After the final proofread manuscript has been received and the last corrections have been performed the manuscript will be published. The manuscript will be published in the current issue of the journal, and the author will be promptly informed as soon as the article is available online. In some cases, namely in special issues, the publication may be delayed in order to guarantee that all articles are published simultaneously, but the author will always be informed should that be the case.
Marketing & Promotion
Outreach or public engagement is a flourishing initiative in academic publishing. We feel that sharing knowledge with the public can drive progress.
Article Processing charges:As an open access publisher, Applis journals are committed to ensure permanent and universal free access to all published articles, unlike closed-access journals which limit their readership to those able to pay subscription fees. This means that Applis Publisher does not receive any income from either subscriptions or article views/downloads. The current publication fee in all Applis journals is $1090 for all research and review articles and with lower fees for case Reports and communications, which are both $650.
Authors are asked to pay APC’s upon acceptance of their article. These charges are used to finance the whole publication and archiving process, including peer review, editing, proof-reading and copy-editing, and hosting and maintenance.
Waiver Policy:We offer a partial fee waiver for individual authors or author groups affiliated with a university or institute in Low-income economies as defined by the World Bank. Waiver requests during or after peer-review will not be considered. Requests will be assessed on a case-by-case basis and may be granted in cases of genuine need. Due to the numerous costs associated to open access publishing, all Applis Journals can only accept to process a limited number of waived submissions per issue. Please mail your request for a waiver of the publication fee to firstname.lastname@example.org before submitting your manuscript. Requests for waivers for manuscripts that are already under peer review or have been typeset will not be granted.
Color illustrations are free of charge, just as supplemental material.
The author’s university or institution may cover the publication costs for articles resulting from research undertaken at the university or institution.
Applis is an international open-access scientific publisher that showcases high quality research and innovative ideas in its endeavor to foster excellence in science and medicine thus making an impact on healthcare and practice for the benefit of Society.
Each Applis OA journals offers the highest standards of peer review, overseen by expert editors and editorial boards. We’re proud of the friendly and constructive approach we take with all our potential authors. Our editorial teams evaluate submissions on the grounds of relevance, sound methodology, and clarity, rather than the predicted level of future importance.
Our peer review process is double blind.
There is no restriction on the length of an article, or the number of figures, tables or supplementary files, but we do ask all authors to be concise.
Larger tables, movie/media files, datasets or other supporting information can be submitted and published as supplementary files.
We do not charge page or color charges.
We publish all kinds of academic Articles, such as Original Research Articles, Review Articles, and Clinical Case Studies.
After reviewing our Guidelines for Authors, you can submit your manuscript and other files as email attachments to our Editorial Office. You will receive the confirmation that we have received your files.
We understand that authors wish to see their articles published as quickly as possible. At the same time authors value high standards in copy editing, proofing, and final presentation. We aim to publish articles as quickly as possible whilst providing a quality production service. Our target is 21 days.
No. Articles are published online only and are provided in PDF and HTML format. We may offer additional printing services on request.
Applis is an open access publisher, with all articles immediately free to be read by anyone worldwide. We do not request any submission charge.
The current publication fee in all Applis journals is $1090 for all research and review articles and with lower fees for case Reports and communications, which are both $650.
Authors are asked to pay APCs upon acceptance of their article.
These charges are used to finance the whole publication and archiving process, including peer review, editing, proof-reading and copy-editing, and hosting and maintenance of the journal archives.
We offer a partial fee waiver for individual authors or author groups affiliated with a university or institute in Low-income economies as defined by the World Bank. Waiver requests during or after peer-review will not be considered. Requests will be assessed on a case-by-case basis and may be granted in cases of genuine need. Due to the numerous costs associated to open access publishing, all Applis Journals can only accept to process a limited number of waived submissions per issue.
Specific instructions on how to make this payment will be provided to authors at the time of acceptance.
As the corresponding author of the manuscript you are responsible for making or arranging the payment (for instance, via your institution) upon editorial acceptance of the manuscript.
The authors retain the copyright of all their work published in Applis Journals. All articles published in Applis Journals are open access and are licensed under Creative Commons Attribution 4.0 International License, which means the articles are universally and freely available online for anyone to download and adapt their work, provided proper attribution is given.